-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Small bowel cancer is a serious gastrointestinal tumor that usually has a lower incidence but has been on the rise
On September 14, 2022, the Tang Fuhui team of the Biomedical Frontier Innovation Center (BIOPIC) of Peking University worked closely with the Fu Wei team of general surgery of the Third Hospital of Beijing Medical University to publish a paper entitled Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in Small bowel adenocarcinomas research paper
The study sequenced single-cell transcriptomes of primary tumor samples, some paracancer samples, and some metastatic samples from 12 patients with small bowel cancer, including the duodenum, jejunum, and ileum, which make up the main intestinal segments
1.
The tumor progression relationship between these four subtypes of cancer cells was further determined by quasi-time path analysis and differentiation entropy analysis, that is, starting from cell cycle enriched cancer cells, passing through mitochondrial function enriched cancer cells, and finally progressing to metabolically exuberant cancer cells or epithelial mesenchymal transformation characteristics enriched cancer cells
2.
The finding suggests that inhibiting the epithelial mesenchymal transformation process in small bowel cancer is likely to slow the depletion of CD8-positive T cells in small bowel cancer tumor tissue, thus providing new enlightenment
3.
This suggests that the current clinical treatment plan for small bowel cancer is worth re-evaluating with reference to the clinical first-line treatment plan for colorectal cancer in any small bowel segment, and the clinical diagnosis and treatment plan for small bowel cancer in the duodenal segment may be more effective
4.
Vracetezia is a small molecule inhibitor of PLK1 kinase that has been approved by the FDA for the treatment of acute myeloid leukemia
Yang Jingwei, Ph.
Thesis Link:
